An AHP analysis of commercial insurance claims finds that guideline-recommended evaluation and first-line fertility treatment are frequently incomplete — and in some cases contraindicated — by the time IVF is initiated.
A recent AHP study finds that commonly cited IVF cost figures materially understate the true cost of a fertility benefit, with a total incremental cost of approximately $54,400 per IVF-conceived birth.
Patients with multiple chronic diseases constitute a small minority of the total population but the majority of healthcare costs. These patient’s healthcare needs cannot be understood...
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, and payers (through their formulary strategies). While previous...
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin making decisions about coverage not only for Amjevita but for all the other Humira...
There is a coming wave of changes arriving soon to the pharmacy market in the form of biosimilars. And that coming wave has a big event in 2023: the launch of Humira biosimilars, which...
I read the 725-page draft of the Deficit Reduction Act[1] so you don’t have to. Well, I skimmed 427 pages of it while focusing on the 164 pages which make significant changes to prescription drugs. This article outlines...
